Finalists 2023

By Recordati Rare Diseases. Roche Molecular Work Area. By Roche Diagnostics GmbH.

Sponsors

Sponsor of: At Recordati Rare Diseases, we focus on the few - those affected by rare diseases. ... Recordati Rare Diseases is a pharmaceutical company that provides treatment for patients with rare diseases.

New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease

Recordati Rare Disease has revealed new data from a phase 3 trial of its Cushing’s disease treatment Isturisa. ... The normalisation of mUFC levels represents an ‘important’ treatment goal, Recordati said in a statement, by potentially reducing

FDA approves Recordati’s Cushing disease drug Isturisa

Recordati is expecting peak sales of Isturisa of more than $100m a year, according to chief executive Andrea Recordati. ... Patent protection extends to 2031 for Isturisa and 2026 for Signifor LAR, according to Recordati, which had total revenues of

1 2 3 4 5 6 7 8 [ Next 5 results ]